FDA authorizes limited prescriptions of Paxlovid by pharmacists
The Food and Drug Administration today authorized state-licensed pharmacists to prescribe Paxlovid (nirmatrelvir and ritonavir) to patients as a treatment for those at high risk of severe COVID-19. Because Paxlovid must be taken within five days of symptom onset, the change could spur expanded access and more-timely treatment of eligible patients. The change was made through an amended emergency use authorization.
Related News Articles
Headline
The Food and Drug Administration yesterday published an announcement from Otsuka ICU Medical saying that the company issued a voluntary recall for a mislabeled…
Headline
A study published Oct. 30 by the American Heart Association found that people have an elevated risk of heart attack and stroke following flu and COVID-19…
Headline
The Centers for Disease Control and Prevention released an advisory Oct. 29 on three unrelated cases of clade I mpox recently identified in California. The…
Perspective
Getting an annual flu vaccination is the best way to prevent flu and its potentially serious complications. The Centers for Disease Control and Prevention…
Headline
There have been 1,596 confirmed cases of measles across the U.S. this year, according to the latest data from the Centers for Disease Control and Prevention.…
Headline
The AHA’s social media toolkit for spreading awareness of the flu focuses on the beginning of fall and the availability of the flu vaccine for at-risk,…